Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome

NARecruitingINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

October 22, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Irritable Bowel Syndrome (IBS)Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Interventions
DEVICE

Gelsectan®

Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).

DRUG

Placebo

Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).

Trial Locations (8)

20122

NOT_YET_RECRUITING

IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Milan

28034

RECRUITING

Hospital Universitario Ramón y Cajal, Madrid

35128

NOT_YET_RECRUITING

Azienda Ospedale Università Padova, Padua

40138

NOT_YET_RECRUITING

IRCCS Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola, Bologna

56124

NOT_YET_RECRUITING

Azienda Ospedaliero Universitaria Pisana (AOUP), Pisa

80131

RECRUITING

AOU Federico II di Napoli, Napoli

00189

NOT_YET_RECRUITING

S. Andrea University Hospital, Roma

08035

RECRUITING

Hospital Universitario Vall d´Hebron, Barcelona

All Listed Sponsors
lead

Devintec Sagl

INDUSTRY